# APR 16.J10

# 510(k) Summary

# Introduction

According to the requiremenits of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics   
9115 Hague Road, P.O. Box 50416   
Indianapolis, IN 46250-0416   
317-521-3577   
Contact Person: Kelly Colleen O'Maine Adams   
Phone: 317-521-3577   
Fax: 317-521-2324   
Email: colleen.adams@roche.com Secondary Contact: Stephanie Greeman Phone: 317-521-2458   
Fax: 317-521-2324   
Email: stephanie.greeman@roche.com

Date Prepared: March 17, 2010

# Device Name

Proprietary name: Elecsys TSH CalCheck 5   
Common name: TSH CalCheck 5   
Classification name: Single (specified) analyte controls (assayed and   
unassayed)

# Predicate device

The Elecsys TSH CalCheck 5 is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys CalCheck TSH (K963147).

Device Description

The Elecsys TSH CalCheck 5 is a lyophilized product consisting of TSH in equine serum matrix. During manufacture, the analyte is spiked into the matrix at the desired concentration levels.

# Intended use

The Elecsys TSH CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys TSH reagent on the indicated Elecsys cobas e immunoassay analyzers.

The table below compares Elecsys TSH CalCheck 5 with the predicate device, Elecsys CalCheck TSH (K963147).

Comparison Table   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Elecsys CalCheck TSH(K963147)</td><td rowspan=1 colspan=1>Elecsys TSH CalCheck 5</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For use in the verification of thecalibration established by theElecsys TSH reagent on theindicated Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>The Elecsys TSH CalCheck 5 is anassayed control for use incalibration verification and for usein the verification of the assay rangeestablished by the Elecsys TSHreagent on the indicated Elecsyscobas e immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Three</td><td rowspan=1 colspan=1>Five</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Reconstitute the contents of Check1, Check 2 and Check 3 withexactly 1.0 mL distilled ordeionized water. Allow the bottle tostand closed for 15 minutes. Mixgently by inversion to ensurehomogeneity.</td><td rowspan=1 colspan=1>Reconstitute Check 1, Check 2,Check 3, Check 4, and Check 5with exactly 1.0 mL distilled ordeionized water. Allow to standclosed for 15 minutes, then mixgently by inversion.</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Siore at 2-8Â°C until expirationdateReconstituted:20 - 25C : 4 hrs</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Equine serum matrix</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Performance Characteristics

The Elecsys TSH CalCheck 5 was evaluated for value assignment and stability.

Roche Diagnostics Roche Professional Diagnostics c/o Ms. Kelly Colleen O'Maine Adams Regulatory Affairs Consultant 9115 Hague Road, PO Box 50416 Indianapolis, IN 46250-0416

Re: k093836 Trade Name: Elecsys TSH CalCheck 5 Regulation Number: 21 CFR $\ S 8 6 2 . 1 6 6 0$ Regulation Name: Quality control material (assayed and unassayed). Regulatory Class: Class I reserved Product Codes: JJX Dated: February 08, 2010 Received: February 12, 2010

Dear Ms. O'Maine Adams:

This letter corrects our substantially equivalent letter of April 15, 2010.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/bef188b58300d5fe38f79c997bfb20201f8ba49f69eb8faa1b509ea389f3e5c2.jpg)

Courtney C. Harper, Ph.D.   
Directr   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known):

Device Name: Elecsys TSH CalCheck 5

Indication For Use:

The Elecsys TSH CalCheck 5 is an assayed control for use in calibration verification and for use in the verification of the assay range established by the Elecsys TSH reagent on the indicated Elecsys and cobas e immunoassay analyzers.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/4c8361d0061cacc22567cb4b1dd800cec653f249f98c880f7e078b1719ca3d47.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety